New obesity drug BGM0504 takes on tirzepatide in Head-to-Head trial
NCT ID NCT06911203
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial compares a new drug, BGM0504, to the existing weight-loss drug tirzepatide in 90 adults with obesity (BMI 35-45) who do not have diabetes. Participants will receive one of the two drugs for 26 weeks to see which leads to greater weight loss and improvements in health measures like waist size and blood pressure. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BGM0504 (a drug) compared to tirzepatide
- What this could lead to
- If BGM0504 works as well or better than tirzepatide, it could offer a new weight-loss option for people with obesity.
- What could go wrong
- This is an early Phase 2 trial with only 90 people, so results may not apply broadly. Side effects or lack of effectiveness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?